

## Efficacy and safety of compared to

The information presented in the summary of findings table below comes from a living network meta-analysis that combines all the available evidence on drug therapies for COVID-19. This statistical approach allows us to obtain estimates of effect for all potential comparisons, even those that have not been compared head-to-head in trials. We present the most trustworthy estimates of effect, based on the GRADE approach.

### Comparison of to

#### Summary of Findings Table

Population: Patients with COVID-19 at any severity

Outcome	N studies / participants with direct evidence	Relative effect estimates	Absolute effect estimates	Certainty of the Evidence	Plain language summary	Source of highest certainty estimate
Mortality (closest to 90 days)	RCTs; patients	N/A	N/A		#N/A	
Mechanical ventilation (closest to 90 days)	RCTs; patients	N/A	N/A		No data found	#N/A
AE leading to discontinuation (within 28 days)	RCTs; patients	N/A	N/A	#N/A	No data found	#N/A
Viral clearance closest to 7 days ( $\pm$ 3 days)	RCTs; patients	N/A	N/A	#N/A	No data found	1
Duration of mechanical ventilation (in days)	RCTs; patients	N/A	N/A		No data found	
Length of hospital stay (in days)	RCTs; patients	N/A	N/A	#N/A	No data found	#N/A
Time to symptom resolution	RCTs; patients	Ratio of Means: 0 (95% CI 0 - 0)	N/A		No data found	#N/A
Time to viral clearance (in days)	RCTs; patients	Ratio of Means: 0 (95% CI 0 - 0)	N/A		No data found	
Length of intensive care unit stay (in days)	RCTs; patients	N/A	N/A	#N/A	#N/A	
Admission to hospital (within 28 days)	RCTs; patients	N/A	N/A		No data found	
Mechanical ventilation-free days (within 28 days; in days)	RCTs; patients	N/A	N/A		No data found	

Abbreviations: AE, *adverse events*; 95% CI, *95% credible interval*; NMA, *network meta-analysis*; N/A, *not applicable*; RCT, *randomized control trial*

GRADE Working Group grades of evidence

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

---

1. The guideline development group did not consider viral clearance, time to viral clearance, length of ICU stay, or mechanical ventilator-free days critical for decision-making. Therefore, we did not include these outcomes in the current update of our NMA. Evidence for these outcomes based on the previous iteration of the NMA can be viewed in this summary of findings table.

[www.covid19Imna.com](http://www.covid19Imna.com)